EASL mourns the passing of Professor Stephanos J Hadziyannis, who died peacefully on Monday 17 November. His loss is deeply felt across the hepatology community, where he was regarded as a visionary clinician scientist and one of the most influential figures of his generation.
Professor Hadziyannis dedicated his career to advancing the understanding and treatment of viral hepatitis, liver disease and related immunological conditions. His work focused particularly in the areas of hepatitis B and C, hepatocellular carcinoma, antiviral therapy and the complex immunology of chronic viral infections. For decades, he illuminated paths forward in fields where knowledge had been limited and where progress required both courage and exceptional scientific clarity.
His early insights into HBeAg negative chronic hepatitis B and his demonstration of HBV DNA in serum and HBcAg in the liver of patients with active inflammation challenged established thinking and helped redefine the natural history of the disease. These pioneering contributions were met initially with scepticism, yet they ultimately became foundational to the global understanding of hepatitis B.
His leadership was central to the development of EASL Clinical Practice Guidelines for chronic hepatitis B, which continue to guide clinicians worldwide.
Colleagues remember him just as strongly for his integrity, warmth and intellectual generosity. He inspired younger researchers, encouraged bold questions and fostered a spirit of critical thinking that uplifted the entire field.
Messages from friends and collaborators speak of a giant in hepatology, a remarkable colleague and a cherished friend. Many recall his ability to challenge dogma with grace, his deep commitment to scientific precision and his constant willingness to support others. His presence at scientific meetings, including those he helped shape in Athens, will be profoundly missed.
EASL extends its sincere condolences to his family, friends and colleagues.